The Cost-Effectiveness of Continuous Glucose Monitoring in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Continuous glucose monitoring (CGM) has been found to improve glucose control in type 1 diabetic patients. We estimated the cost-effectiveness of CGM versus standard glucose monitoring in type 1 diabetes. RESEARCH DESIGN AND METHODS: This societal cost-effectiveness analysis (CEA) was conducted in trial populations in which CGM has produced a significant glycemic benefit (A1C ≥7.0% in a cohort of adults aged ≥25 years and A1C <7.0% in a cohort of all ages). Trial data were integrated into a simulation model of type 1 diabetes complications. The main outcome was the cost per quality-adjusted life-year (QALY) gained. RESULTS: During the trials, CGM patients experienced an immediate quality-of-life benefit (A1C ≥7.0% cohort: 0.70 quality-adjusted life-weeks [QALWs], P = 0.49; A1C <7.0% cohort: 1.39 QALWs, P = 0.04) and improved glucose control. In the long-term, CEA for the A1C ≥7.0% cohort, CGM was projected to reduce the lifetime probability of microvascular complications; the average gain in QALYs was 0.60. The incremental cost-effectiveness ratio (ICER) was $98,679/QALY (95% CI −60,000 [fourth quadrant] to −87,000 [second quadrant]). For the A1C <7.0% cohort, the average gain in QALYs was 1.11. The ICER was $78,943/QALY (15,000 [first quadrant] to −291,000 [second quadrant]). If the benefit of CGM had been limited to the long-term effects of improved glucose control, the ICER would exceed $700,000/QALY. If test strip use had been two per day with CGM long term the ICER for CGM would improve significantly. CONCLUSIONS: Long-term projections indicate that CGM is cost-effective among type 1 diabetic patients at the $100,000/QALY threshold, although considerable uncertainty surrounds these estimates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Go, A. S., Hylek, E. M., Phillips, K. A., Chang, Y., Henault, L. E., Selby, J. V., & Singer, D. E. (2001) · JAMA · doi:10.1001/jama.285.18.2370 · Cited by 6,205
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
(2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.193 · Cited by 653
Clarke, P. M., Gray, A. M., Briggs, A., Farmer, A. J., Fenn, P., Stevens, R. J., Matthews, D. R., Stratton, I. M., Holman, R. R., & on behalf of the UK Prospective Diabetes Study (UKPDS) Group (2004) · Diabetologia · doi:10.1007/s00125-004-1527-z · Cited by 615 · cited 2×
“For mortality related to diabetes complications, we used mortality prediction models developed with type 2 diabetes data (16).”
Braithwaite, R. S., Meltzer, D. O., King, J. T., Leslie, D., & Roberts, M. S. (2008) · Medical Care · doi:10.1097/mlr.0b013e31815c31a7 · Cited by 579 · cited 1×
“Recent studies suggest that the acceptable ICER threshold is between $109,000 and $297,000/QALY, above the commonly discussed $50,000/ QALY threshold (22).”
Self-citationThe effect of continuous glucose monitoring in well-controlled type 1 diabetes
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0108 · Cited by 399
ACCOUNTING FOR DROPOUT BIAS USING MIXED-EFFECTS MODELS
Mallinckrodt, C. H., Clark, W. S., & David, S. R. (2001) · Journal of Biopharmaceutical Statistics · doi:10.1081/bip-100104194 · Cited by 398 · cited 1×
“Experienced utilities at baseline, week 13, and week 26 were modeled using a random-effects linear model (9,10).”
Vijan, S. (2000) · JAMA · doi:10.1001/jama.283.7.889 · Cited by 295
Cited by
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationWearable Continuous Glucose Monitoring Sensors: A Revolution in Diabetes Treatment
Cappon, G., Acciaroli, G., Vettoretti, M., Facchinetti, A., & Sparacino, G. (2017) · Electronics · doi:10.3390/electronics6030065 · Cited by 237
“Use of CGM sensor is recognized to be not only clinically beneficial for T1D glycaemic control [75,76], but also cost ‐ effective in the long term [77,78], despite the fact that only 10% of T1D patients are currently using this technology [79]. also cost-effective in the long term [77,78], despite…”
BackgroundFonseca, V. A., Grunberger, G., Anhalt, H., Bailey, T. S., Blevins, T., Garg, S. K., Handelsman, Y., Hirsch, I. B., Orzeck, E. A., Roberts, V. L., et al. (2016) · Endocrine Practice · doi:10.4158/ep161392.cs · Cited by 195
“A 2012 meta-analysis that included 10 trials comparing real time CGM to SMBG and 4 studies comparing SAP with MDI+SMBG supported the superiority of CGM over SMBG and SAP devices over MDI+SMBG in terms A1C reduction without increased risk of hypoglycemia (17).”
BackgroundMethodInfluentialKarter, A. J., Parker, M. M., Moffet, H. H., Gilliam, L. K., & Dlott, R. (2021) · JAMA · doi:10.1001/jama.2021.6530 · Cited by 191
Didyuk, O., Econom, N., Guardia, A., Livingston, K., & Klueh, U. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819899394 · Cited by 175
Kaplan, R. M., & Stone, A. A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143736 · Cited by 144
Blevins, T. C., Bode, B. W., Garg, S. K., Grunberger, G., Hirsch, I. B., Jovanovič, L., Nardacci, E., Orzeck, E. A., Roberts, V. L., & Tamborlane, W. V. (2010) · Endocrine Practice · doi:10.4158/ep.16.5.730 · Cited by 98
Self-citationContinuous glucose monitoring: Current use in diabetes management and possible future applications
Vettoretti, M., Cappon, G., Acciaroli, G., Facchinetti, A., & Sparacino, G. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818774078 · Cited by 96
“The use of CGM sensors is very beneficial for glycemic control, particularly for reducing HbA1c and the frequency of hypoglycemic events,(7-11) and is potentially cost effective in terms of the ratio between costs and quality-adjusted lifeyears.(12-15) Nevertheless, the distribution of CGM sensors has remained limited…”
BackgroundThe Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes
Fonda, S. J., Graham, C., Munakata, J., Powers, J. M., Price, D., & Vigersky, R. A. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816628547 · Cited by 81
The Growing Role of Technology in the Care of Older Adults With Diabetes
Huang, E. S., Sinclair, A., Conlin, P. R., Cukierman-Yaffe, T., Hirsch, I. B., Huisingh-Scheetz, M., Kahkoska, A. R., Laffel, L., Lee, A. K., Lee, S., et al. (2023) · Diabetes Care · doi:10.2337/dci23-0021 · Cited by 73
Self-citationBillings, L. K., Parkin, C. G., & Price, D. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0163 · Cited by 39
Bajgrowicz-Cieslak, M., Alqurashi, Y., Elshereif, M. I., Yetisen, A. K., Hassan, M. U., & Butt, H. (2017) · RSC Advances · doi:10.1039/c7ra11184c · Cited by 32
Hirsch, I. B., & Verderese, C. A. (2017) · Endocrine Practice · doi:10.4158/ep171962.ra · Cited by 22
McQueen, R. B., Breton, M. D., Ott, M., Koa, H., Beamer, B., & Campbell, J. D. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815599551 · Cited by 17
McQueen, R. B., Breton, M. D., Craig, J., Holmes, H., Whittington, M. D., Ott, M. A., & Campbell, J. D. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818769098 · Cited by 12
The Expanding Use of Continuous Glucose Monitoring in Type 2 Diabetes
Dabbagh, Z., McKee, M. D., Pirraglia, P. A., Clements, K. M., Liu, F., Amante, D. J., Shukla, P., & Gerber, B. S. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0536 · Cited by 7
Metadata
- Authors
- Huang, E. S., O'Grady, M., Basu, A., Winn, A., John, P., Lee, J., Meltzer, D., Kollman, C., Laffel, L., Tamborlane, W., Weinzimer, S., Wysocki, T., & the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-03-23
- Volume
- 33
- Issue
- 6
- Pages
- 1269-1274
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2116215834
- Cited by
- 117
- References
- 10
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.